Department of Pharmacy Practice, State University of New York School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA.
Infect Control Hosp Epidemiol. 2012 Jun;33(6):558-64. doi: 10.1086/665731. Epub 2012 Apr 13.
Bloodstream infections due to methicillin-resistant Staphylococcus aureus (MRSA) have been associated with significant risk of in-hospital mortality. The acute physiology and chronic health evaluation (APACHE) II score was developed and validated for use among intensive care unit (ICU) patients, but its utility among non-ICU patients is unknown. The aim of this study was to determine the ability of APACHE II to predict death at multiple time points among ICU and non-ICU patients with MRSA bacteremia.
Retrospective cohort study.
Secondary analysis of data from 200 patients with MRSA bacteremia at 2 hospitals.
Logistic regression models were constructed to predict overall in-hospital mortality and mortality at 48 hours, 7 days, 14 days, and 30 days using APACHE II scores separately in ICU and non-ICU patients. The performance of APACHE II scores was compared with age adjustment alone among all patients. Discriminatory ability was assessed using the c-statistic and was compared at each time point using χ(2) tests. Model calibration was assessed using the Hosmer-Lemeshow goodness-of-fit test.
APACHE II was a significant predictor of death at all time points in both ICU and non-ICU patients. Discrimination was high in all models, with c-statistics ranging from 0.72 to 0.84, and was similar between ICU and non-ICU patients at all time points. APACHE II scores significantly improved the prediction of overall and 48-hour mortality compared with age adjustment alone.
The APACHE II score may be a valid tool to control for confounding or for the prediction of death among ICU and non-ICU patients with MRSA bacteremia.
耐甲氧西林金黄色葡萄球菌(MRSA)引起的血流感染与住院死亡率有显著的相关性。急性生理学和慢性健康评估(APACHE)Ⅱ评分是专为重症监护病房(ICU)患者开发和验证的,但它在非 ICU 患者中的应用效果尚不清楚。本研究的目的是确定 APACHE Ⅱ评分在 ICU 和非 ICU 患者 MRSA 菌血症患者中,在多个时间点预测死亡的能力。
回顾性队列研究。
对 2 家医院的 200 名 MRSA 菌血症患者的数据进行二次分析。
使用逻辑回归模型,分别在 ICU 和非 ICU 患者中,使用 APACHE Ⅱ评分预测总体住院死亡率和 48 小时、7 天、14 天和 30 天的死亡率。在所有患者中,使用年龄调整单独比较 APACHE Ⅱ评分的表现。使用 c 统计量评估判别能力,并使用 χ(2)检验在各个时间点进行比较。使用 Hosmer-Lemeshow 拟合优度检验评估模型校准。
APACHE Ⅱ评分是 ICU 和非 ICU 患者所有时间点死亡的重要预测因素。所有模型的判别能力都很高,c 统计量范围从 0.72 到 0.84,在所有时间点,ICU 和非 ICU 患者之间的判别能力相似。APACHE Ⅱ评分与年龄调整相比,显著提高了对总体和 48 小时死亡率的预测。
APACHE Ⅱ评分可能是一种有效的工具,可以控制混杂因素,或预测 MRSA 菌血症 ICU 和非 ICU 患者的死亡。